133 related articles for article (PubMed ID: 38275149)
1. Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan.
Akakura K; Uemura H; Kawakami S; Yokomizo A; Nakamura M; Nishimura K; Komori T; Ledesma DA
Future Oncol; 2024 Apr; 20(12):781-798. PubMed ID: 38275149
[TBL] [Abstract][Full Text] [Related]
2. A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
Akakura K; Uemura H; Miyazaki K; Stroupe A; Seo C; Uzumcu A; Ledesma DA
Future Oncol; 2021 Dec; 17(36):5103-5118. PubMed ID: 34664992
[TBL] [Abstract][Full Text] [Related]
3. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
[TBL] [Abstract][Full Text] [Related]
4. Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study.
Kawahara T; Miyoshi Y; Ninomiya S; Sato M; Takeshima T; Hasumi H; Makiyama K; Uemura H
Int J Urol; 2022 Sep; 29(9):1079-1084. PubMed ID: 35976620
[TBL] [Abstract][Full Text] [Related]
5. Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.
Badrising SK; Louhanepessy RD; van der Noort V; Kieffer J; Coenen JLLM; Hamberg P; Beeker A; Wagenaar N; Lam M; Celik F; Loosveld OJL; Oostdijk A; Zuetenhorst H; de Feijter JM; Dezentjé VO; Ras-van Spijk S; Vegt E; Haanen JB; van de Poll-Franse LV; Zwart W; Bergman AM
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):248-255. PubMed ID: 34446849
[TBL] [Abstract][Full Text] [Related]
6. Review of Palliative
Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T
J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158
[TBL] [Abstract][Full Text] [Related]
7. Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.
Jiang XY; Atkinson S; Pearson R; Leaning D; Cumming S; Burns A; Azzabi A; Frew J; McMenemin R; Pedley ID
Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e177-e187. PubMed ID: 32448724
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
Matsumoto T; Hori Y; Shiota M; Blas L; Nakamura M; Seki N; Kuroiwa K; Yokomizo A; Morokuma F; Kiyoshima K; Eto M
Int J Urol; 2023 Feb; 30(2):139-146. PubMed ID: 36305673
[TBL] [Abstract][Full Text] [Related]
9. Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy.
Sraieb M; Hirmas N; Conrad R; Marinova M; Essler M; Herrmann K; Ahmadzadehfar H
Medicine (Baltimore); 2020 Sep; 99(38):e22287. PubMed ID: 32957385
[TBL] [Abstract][Full Text] [Related]
10. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513
[TBL] [Abstract][Full Text] [Related]
11. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan.
Chiang PC; Chiang PH; Chen IA; Chen YT; Wang HJ; Cheng YT; Kang CH; Chen CH; Liu YY; Su YL; Chen YH; Luo HL
Medicine (Baltimore); 2023 Feb; 102(5):e32671. PubMed ID: 36749250
[TBL] [Abstract][Full Text] [Related]
14. Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with
Palmedo H; Ahmadzadehfar H; Eschmann S; Niesen A; Schönberger J; Barsegian V; Liepe K; Mottaghy FM; Guan R; Pinkert J; Sandström P; Herrmann K
J Nucl Med; 2023 Sep; 64(9):1392-1398. PubMed ID: 37385670
[No Abstract] [Full Text] [Related]
15. Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer.
Kawaguchi G; Akazawa K; Ikeda T; Ikeda Y; Hara N; Nishiyama T
SAGE Open Med; 2023; 11():20503121231168493. PubMed ID: 37113623
[TBL] [Abstract][Full Text] [Related]
16. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.
Hyväkkä A; Kääriäinen OS; Utriainen T; Löyttyniemi E; Mattila K; Reinikainen P; Sormunen J; Jääskeläinen M; Auvinen P; Minn H; Sundvall M
Cancer Med; 2023 Feb; 12(4):4064-4076. PubMed ID: 36156455
[TBL] [Abstract][Full Text] [Related]
17. Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis.
Turco F; Tucci M; Angusti T; Parente A; Di Stefano RF; Urban S; Pisano C; Samuelly A; Audisio A; Audisio M; Parlagreco E; Ungaro A; Scagliotti GV; Di Maio M; Buttigliero C
Tumori; 2023 Apr; 109(2):233-243. PubMed ID: 35361017
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction.
Cindolo L; Natoli C; De Nunzio C; De Tursi M; Valeriani M; Giacinti S; Micali S; Rizzo M; Bianchi G; Martorana E; Scarcia M; Ludovico GM; Bove P; Laudisi A; Selvaggio O; Carrieri G; Bada M; Castellan P; Topazio L; Boccasile S; Ditonno P; Chiodini P; Schips L
Clin Genitourin Cancer; 2017 Oct; 15(5):520-525. PubMed ID: 28478884
[TBL] [Abstract][Full Text] [Related]
20. Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without
Caffo O; Frantellizzi V; Monari F; Galli L; Costa RP; Pinto C; Tucci M; Baldari S; Facchini G; Bortolus R; Alongi F; Alongi P; Donner D; Fanti S; Sbrana A; Morabito A; Masini C; Zichi C; Pignata S; Borsatti E; Salgarello M; Spada M; De Giorgi U; Lo Re G; Cortesi E; De Vincentis G
Cancer Biother Radiopharm; 2021 Jun; 36(5):391-396. PubMed ID: 33769088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
